MiR-223 exogenous expression sensitizes breast and colon cancer cells expressing mutant p53 to treatment with DNA-damaging drugs and it could inhibit cell proliferation. Overexpression of miR-223 is related to granulocyte-specific lineage. Here, TP53 is linked to colonic neoplasm.